COLL earnings call for the period ending March 31, 2019.
News & Analysis: Collegium Pharmaceutical
Investment-bank analysts think these drugmakers are worth a lot more than the stock market does at the moment.
COLL earnings call for the period ending December 31, 2018.
The company is acquiring a new drug with over $200 million in annual sales, but it won't be cheap.
The FDA is working on ways to encourage the development of abuse-deterrent opioid pain relievers, and that's potentially bad news for this tiny biotech.
Endo International has been asked by the FDA to stop selling Opana ER, clearing the way for greater use of Collegium's competing medicine.
2015 was not a particularly strong year for IPOs, but these five did quite well.
The FDA is a step closer to approving Collegium Pharmaceutical's abuse-deterrent opioid pain-killer.